SEC Comment Letter for Altimmune, Inc. (ALT) (CIK 0001326190) (ALT) — Aug 16, 2019
Altimmune, Inc. (ALT) (CIK 0001326190)
Date: Aug. 16, 2019 · CIK: 0001326190 · Accession: 0000000000-19-012559
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-32587
Letter
August 16, 2019 Vipin K. Garg Chief Executive Officer Altimmune, Inc. 910 Clopper Road, Suite 201S Gaithersburg, Maryland, 20878 Re:Altimmune, Inc. Preliminary Proxy Statement on Schedule 14A Filed August 9, 2019 File No. 001-32587 Dear Dr. Garg: We have reviewed your filing and have the following comment. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Preliminary Proxy Statement on Schedule 14A filed August 9, 2019 Proposal 5 — Approval of the Issuance of our Common Stock in Connection with Milestone Payments..., page 27 1.We note that your proposal to approve the issuance of common stock in connection with future milestone payments is a result of your merger with Spitfire Pharma, Inc. Please revise your proxy statement to provide all of the information relating to Spitfire and the merger that is required by Items 11, 13 and 14 of Schedule 14A, as applicable. Please refer to Note A of Schedule 14A. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameVipin K. Garg Comapany NameAltimmune, Inc. August 16, 2019 Page 2 FirstName LastName Vipin K. Garg Altimmune, Inc. August 16, 2019 Page 2
Please contact Irene Paik at 202-551-6553 or Joe McCann at 202-551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Joseph C. Theis, Jr. - Goodwin Procter LLP
Show Raw Text
August 16, 2019
Vipin K. Garg
Chief Executive Officer
Altimmune, Inc.
910 Clopper Road, Suite 201S
Gaithersburg, Maryland, 20878
Re:Altimmune, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed August 9, 2019
File No. 001-32587
Dear Dr. Garg:
We have reviewed your filing and have the following comment.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comments apply to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A filed August 9, 2019
Proposal 5 — Approval of the Issuance of our Common Stock in Connection with Milestone
Payments..., page 27
1.We note that your proposal to approve the issuance of common stock in connection with
future milestone payments is a result of your merger with Spitfire Pharma, Inc. Please
revise your proxy statement to provide all of the information relating to Spitfire and the
merger that is required by Items 11, 13 and 14 of Schedule 14A, as applicable. Please
refer to Note A of Schedule 14A.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameVipin K. Garg
Comapany NameAltimmune, Inc.
August 16, 2019 Page 2
FirstName LastName
Vipin K. Garg
Altimmune, Inc.
August 16, 2019
Page 2
Please contact Irene Paik at 202-551-6553 or Joe McCann at 202-551-6262 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Joseph C. Theis, Jr. - Goodwin Procter LLP